Effects of Catheter‐based Renal Denervation on Renin‐aldosterone System, Catecholamines, and Electrolytes: A Systematic Review and Meta‐analysis

Xiangyu Yang,Lede Lin,Zhipeng Zhang,Xiaoping Chen

DOI: https://doi.org/10.1111/jch.14590

2022-01-01

Abstract:The Journal of Clinical HypertensionVolume 24, Issue 12 p. 1537-1546 META-ANALYSISOpen Access Effects of catheter-based renal denervation on renin-aldosterone system, catecholamines, and electrolytes: A systematic review and meta-analysis Xiangyu Yang MD, Xiangyu Yang MD Department of Cardiology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorLede Lin MD, Lede Lin MD Department of Urology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorZhipeng Zhang MD, Zhipeng Zhang MD Department of Cardiology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorXiaoping Chen MD, Corresponding Author Xiaoping Chen MD [email protected] orcid.org/0000-0001-7714-3403 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China Correspondence Xiaoping Chen, Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: [email protected]Search for more papers by this author Xiangyu Yang MD, Xiangyu Yang MD Department of Cardiology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorLede Lin MD, Lede Lin MD Department of Urology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorZhipeng Zhang MD, Zhipeng Zhang MD Department of Cardiology, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorXiaoping Chen MD, Corresponding Author Xiaoping Chen MD [email protected] orcid.org/0000-0001-7714-3403 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China Correspondence Xiaoping Chen, Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: [email protected]Search for more papers by this author First published: 02 November 2022 https://doi.org/10.1111/jch.14590 Xiangyu Yang and Lede Lin contribute equally to this article. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract In recent years, catheter-based renal denervation (RDN) has emerged as a promising instrumental therapy for hypertension. The interruption of sympathetic nervous system was regarded as a possible mechanism for RDN regulating blood pressure. While the results reflected by renin-angiotensin-aldosterone system (RAAS), catecholamines and electrolytes remained inconsistent and was never systematically assessed. Pubmed, Embase, and Web of Science were comprehensively searched from inception to September 5, 2021. Studies that evaluated the effects of RDN on RAAS, catecholamines, and electrolytes were identified. Primary outcomes were changes in RAAS hormones after RDN, and secondary outcomes involved changes in plasma norepinephrine, serum, and urinary sodium and potassium. Out of 6391 retrieved studies, 20 studies (two randomized controlled studies and 18 observational studies) involving 771 persons were eventually included. Plasma renin activity had a statistically significant reduction after RDN (0.24 ng/mL/h, 95% CI 0.04 to 0.44, P = .02). While no significant change was found regarding plasma aldosterone (1.53 ng/dL, 95% CI -0.61 to 3.67, P = .16), norepinephrine (0.42 nmol/L, 95% -0.51 to 1.35, P = 0.38), serum sodium and potassium (0.16 mmol/L, 95% CI -0.17 to 0.49, P = .34; -0.02 mmol/L, 95% CI -0.09 to 0.04, P = .48, respectively), and urinary sodium and potassium (3.95 mmol/24 h, 95% CI -29.36 to 37.26, P = .82; 10.22 mmol/24 h, 95% CI -12.11 to 32.54, P = .37, respectively). In conclusion, plasma renin activity significantly decreased after RDN, while no significant change was observed in plasma aldosterone, plasma norepinephrine, and serum and urinary electrolytes. 1 INTRODUCTION Hypertension (HTN) remains one of the heaviest burdens of public health worldwide, as the number of adults affected by HTN maintains an upward trend, which is predicted to reach a total of 1.56 billion in 2025.1 Though with the popularization of antihypertensive drugs, the treatment and control rates of HTN in some countries were still low.2 According to existed reports, blood pressure (BP) was still not controlled in 13.72-16.24% hypertensives under treatment of at least triple combinations of drugs,3 which was defined as resistant hypertension (RH). To meet the growing needs and achieve better BP control, catheter-based renal denervation (RDN) emerged as a promising interventional approach to complement pharmaceutical therapies in HTN patients, especially in those with RH.4-6 The important role of the sympathetic nervous system in the pathogenesis of HTN has been proved by previous research.7 The blockage of renal efferent sympathetic nerves was also regarded as part of the mechanisms of RDN reducing BP, through altering renal blood flow, increasing urinary salt excretion, and decreasing renin release from the kidney.8 While the results regarding the direct effect of RDN on the sympathetic nervous system, reflected by changes in plasma renin, aldosterone, catecholamines, and subsequent serum and urinary electrolytes, are inconsistent and have never been systematically assessed. The objective of this study was to undertake a systematic review and meta-analysis of research to determine whether such changes existed after the procedure of catheter-based RDN in HTN patients. 2 METHODS We conducted the systematic review and meta-analysis according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analyses) guidelines.9 Search strategy The goal of the search was to find studies that documented the changes in plasma renin, plasma aldosterone, plasma and urinary catecholamines, and serum and urinary electrolytes in hypertensive objectives after RDN. The following databases were searched from their inception until September 5, 2021, including Embase, Pubmed, and Web of Science. Each query group was created using Mesh-terms along with free terms (renal denervation, renal-angiotensin-aldosterone system, catecholamines, sodium, potassium), and was eventually combined into a single search. No restriction was placed on the publication date, sample size, follow-up time, or language type. Detailed search strategies are available in Supplementary file 1. Study selection The search results were screened independently by two reviewers. Inclusion criteria were studies reporting data on plasma renin, plasma aldosterone, plasma and urinary catecholamines, serum and urinary sodium or potassium before and after RDN procedure in HTN patients. Studies with at least one outcome of interest above were included. Only full-text published articles were qualified for inclusion. Exclusion criteria were as follows: 1. Conference abstracts, case reports, reviews, editorials and letters; 2. Animal studies; 3. Articles with incomplete data; 4. Studies not targeted at hypertension patients. As for publications from the same population, reporting on different follow-up period data, only the one with the longest follow-up time was used for the overall analysis. Discrepancies in the screening results between the two reviewers were solved by further discussion and consensus. Outcomes The primary outcomes were changes in RAAS hormones after RDN, including plasma renin and plasma aldosterone. The secondary outcomes involved changes in plasma catecholamines, serum and urinary sodium and potassium, and blood pressure. Data extraction and quality assessment Two reviewers independently extracted data and assessed study quality. Information about studies characteristics (first author, year of publication, country, study design, sample size, type of patients, follow-up time, type of RDN catheter), patients characteristics (mean age), and outcomes data (changes in plasma renin, plasma aldosterone, plasma catecholamines, plasma and urinary sodium and potassium, blood pressure) was extracted. With regard to studies reporting outcome data with inconsistent units, or those presenting data not in the form of mean ± standard deviation, we tried to convert them as possible using reasonable methods,10-12 before performing analysis (ng/mL/h for renin; ng/dL for aldosterone; nmol/L for norepinephrine; mmol/L for serum electrolytes; mmol/24 h for urinary electrolytes; mmHg for blood pressure). Only data from the RDN treatment arm was extracted for analysis. Quality assessment was conducted on all included articles. For all the studies, methodological index for non-randomized studies (MINORS)13 was applied in the assessment. MINORS comprised 12 items in total, including eight items for non-comparative studies, and four additional items for comparative items. Each item should be scored from 0 to 2, representing not reported, reported but inadequate, and reported and adequate, respectively. The global ideal score was 16 for single-arm studies. A total score of more than 12 points indicated high quality, 8–12 points indicated intermediate quality, and a score of less than 8 points indicated low quality. Data synthesis and analysis All statistical analyses were performed using Review Manager 5.3 software (Cochrane, London, UK). Pooled outcomes were reported as mean difference (MD) with 95% confidence interval (CI), in a random model. I2 test was utilized to detect potential heterogeneity. I2 ≤ 50% was considered to have acceptable heterogeneity. Meta-regression analysis was used to evaluate the relationship between plasma renin activity (PRA) and BP. Statistical power was set at 0.05 on two sides. The results were presented as forest plots. Funnel plots were applied to detect potential publication bias. Egger test and Begg test were used to calculate significance of publication bias. If Egger test or Begg test was significant, then trim-and-fill analysis was utilized to input linear estimator to adjust publication bias. 3 RESULTS Study selection and characteristics The search strategy identified a total of 7546 records from the three databases. After removing the duplicates and excluding results not meeting the inclusion and exclusion criteria, 20 articles were eventually retrieved for data extraction. Detailed process is presented in Figure 1. FIGURE 1Open in figure viewerPowerPoint Flowchart of study selection The studies were published between 2011 and 2021. Among the 20 identified articles, 2 of them were RCTs, and the other 18 were observational studies. Most of the included studies reported on patients from Europe, Australia, and East Asia. A total of 771 persons were involved. The mean age of the patients from each study ranged from 51.2 to 68 years. Follow-up duration ranged from 0.5 to 72 months. Ten studies reported data on plasma renin,14-23 nine studies on plasma aldosterone,14-16, 18, 19, 21-24 two studies on plasma norepinephrine,20, 25 seven studies on serum sodium,23, 24, 26-30 nine studies on serum potassium,23, 24, 26-32 five studies on urinary sodium,18, 20, 24, 26, 33 and two studies on urinary potassium.24, 26 The characteristics of included studies are summarized in Table 1. TABLE 1. Baseline characteristics of included studies First Author Year Area Study Design Sample Size Age, y Follow-up, m Catheter Type Outcomes M Voskuil 2011 Netherlands Observational Study 11 68 ± 12 1 UK RAAS H Ahmed 2012 Czech Republic Observational Study 5 – 3 Irrigated-tip Celsius Thermocool ablation catheter RAAS W Li 2013 China Observational Study 10 52.2 ± 11.9 0.5 Celsius RAAS M Hamza 2014 Egypt Observational Study 55 58 ± 7 6 Symplicity RAAS J Poss 2015 Germany Observational Study 137 63 ± 1 6 Symplicity Electrolytes RAAS S Ewen 2015 Italy Observational Study 30 61.9 ± 9.9 6 Symplicity Flex RAAS LC Dobrowolski 2018 Italy Observational Study 21 60(53-70) 1.5 Symplicity Electrolytes RAAS Catecholamines L Feyz 2020 Netherland Observational Study 60 64 ± 9 6 Paradiese, Vessix V2™, Symplicity, OneShot, EnligHTN RAAS Catecholamines CJ Kim 2021 South Korea Observational Study 16 56.5 ± 14.8 3 DENEX RAAS F Mahfoud 2021 Eight countries RCT 126 – 3 Symplicity Spyral, Symplicity G3 Electrolytes RAAS C Ott 2017 Germany Observational Study 41 61.0 ± 9.2 6 Symplicity and Flex Electrolytes RAAS M Ezzahti 2014 Netherlands Observational Study 17 51.2 ± 9.4 6 Symplicity Catecholamines D Hering 2012 Australia Observational Study 15 61 ± 9 3,6 UK Electrolytes D Hering 2013 Poland Observational Study 40 60 ± 11 3 Symplicity Electrolytes D Hering 2016 Australia Observational Study 65(G1), 16(G2), 10(G3) 63 ± 10(G1) 63 ± 11(G2) 67 ± 8(G3) 3,6 Symplicity Electrolytes J Rosa 2017 Czech Republic RCT 52 56 ± 12 24 Symplicity Electrolytes U Kampmann 2017 Denmark Observational Study 8 62.5 ± 2.55 6 Simplicity Electrolytes C Tsioufis 2014 Greece Observational Study 14 55.4 ± 8.9 6 EnligHTN Electrolytes OU Bergland 2020 Norway RCT 9 57 ± 10.9 6,36,72 UK Electrolytes Y Vuignier 2018 Switzerland Observational Study 13 56.1 ± 9.9 1,12 Symplicity Flex, EnligHTN IV Electrolytes RCT, randomized control trials; RAAS, renin-angiotensin-aldosterone system. Quality assessment Quality assessment was performed using the MINORS score system. The scores of all the included studies ranged from 13 to 16 points, which were acceptable for the present meta-analysis (Table 2). TABLE 2. Quality assessment of included studies Study I II III IV V VI VII VIII Total M Voskuil, 2011 2 2 2 2 2 2 2 0 14 H Ahmed, 2012 2 2 2 2 2 2 1 0 13 W Li, 2013 2 2 2 2 2 1 2 0 13 M Hamza, 2014 2 2 2 2 2 2 1 0 13 J Poss, 2015 2 2 2 2 2 2 1 0 13 S Ewen, 2015 2 2 2 2 2 2 2 0 14 LC Dobrowolski, 2018 2 2 2 2 2 2 2 2 16 L Feyz, 2020 2 2 2 2 2 2 2 0 14 CJ Kim, 2021 2 2 2 2 2 2 2 0 14 F Mahfoud, 2021 2 2 2 2 2 2 2 0 14 C Ott, 2017 2 2 2 2 2 0 2 2 14 M Ezzahti, 2014 2 2 2 2 2 2 1 0 13 D Hering, 2012 2 2 2 2 2 2 1 0 13 D Hering, 2013 2 2 2 2 2 2 2 0 14 D Hering, 2016 2 2 2 2 2 2 2 0 14 J Rosa, 2017 2 2 2 2 2 2 2 2 16 U Kampmann, 2017 2 2 2 2 2 2 1 0 13 C Tsioufis, 2014 2 2 2 2 2 2 2 0 14 OU Bergland, 2020 2 2 2 2 2 2 2 0 14 Y Vuignier, 2018 2 2 2 2 2 2 2 0 14 Numbers I–VIII in heading represented: I, a clearly stated aim; II, inclusion of consecutive patients; III, prospective collection of data; IV, endpoints appropriate to the aim of the study; V, unbiased assessment of the study endpoint; VI, follow-up period appropriate to the aim of the study; VII, loss of follow up less than 5%; VIII, prospective calculation of the study size. Effect of RDN on plasma renin and blood pressure Comparisons of plasma renin activity levels before and after RDN were extracted in ten studies (n = 330). As presented in Figure 2, pooled PRA showed a significantly decrease after RDN (0.24 ng/mL/h, 95% CI 0.04 to 0.44, P = .02). No apparent heterogeneity or publication bias was observed (I2 = 0, Egger test = 0.4210, Begg test = 0.7205). FIGURE 2Open in figure viewerPowerPoint (A) Forest plot and funnel plot of overall PRA level before and after RDN. (B) Forest plot of ambulatory SBP before and after RDN. (C) Forest plot of ambulatory DBP before and after RDN. (D) Forest plot of office SBP before and after RDN. € Forest plot of office DBP before and after RDN. PRA, plasma renin activity; RDN, catheter-based renal denervation; SBP, systolic blood pressure; DBP, diastolic blood pressure Blood pressure data were subsequently extracted from those ten studies, out of which 5 (n = 134) reported on changes in ambulatory blood pressure, and 8 (n = 340) reported on office blood pressure. As shown in Figure2, both 24-hour mean systolic blood pressure (SBP) and 24-h mean diastolic blood pressure (DBP) significantly decreased after RDN (11.53 mmHg, 95% CI 6.35-16.72, P < .0001; 5.36 mmHg, 95% CI 2.47-8.26, P = .0003, respectively). No apparent heterogeneity or publication bias was observed (I2 = 29%, Egger test = 0.8672, Begg test = 0.8065; I2 = 0, Egger test = 0.5207, Begg test = 0.2207, respectively). Office SBP and DBP also showed reductions after the procedure (20.99 mmHg, 95% CI 16.41-25.58, P < .0001; 10.99 mmHg, 95% CI 9.12 to 12.85, P < .0001, respectively). Relatively high heterogeneity was observed in office SBP, and no apparent publication bias was seen (I2 = 75%, Egger test = 0.4963, Begg test = 0.5362; I2 = 47%, Egger test = 0.5015, Begg test = 0.5362, respectively). Meta-regression analyses were performed between baseline PRA and changes in BP values after the surgery. Baseline PRA was positively associated with 24-hour SBP reduction (coefficient = 0.017, 95% CI 0.002-0.032, P = .025, Table S1). Effect of RDN on plasma aldosterone Changes in plasma aldosterone levels were available in nine studies (n = 341). As displayed in Figure 3A, plasma aldosterone levels tended to decrease after RDN, while the change was not statistically significant (1.53 ng/dL, 95% CI -0.61 to 3.67, P = .16). High heterogeneity was observed between these studies (I2 = 86%). No significant publication bias was found (Egger test = 0.1276, Begg test = 1.0830). FIGURE 3Open in figure viewerPowerPoint (A) Forest plot and funnel plot of overall PAC level before and after RDN. (B) Forest plot and funnel plot of overall norepinephrine level before and after RDN. PAC, plasma aldosterone concentration; RDN, catheter-based renal denervation Effect of RDN on plasma catecholamines Two studies referred to plasma norepinephrine changes after RDN (n = 38). As shown in Figure 3B, no significant difference was found after RDN (0.42 nmol/L, 95% CI -0.51 to 1.35, P = .38) with moderate heterogeneity (I2 = 57%). Effect of RDN on serum and urinary electrolytes Seven studies reported changes in serum sodium after RDN (n = 373) and nine studies reported on serum potassium (n = 396), with one study containing three subgroups. Neither serum sodium nor serum potassium was significantly altered (0.16 mmol/L, 95% CI -0.17 to 0.49, P = .34; -0.02 mmol/L, 95% CI -0.09 to 0.04, P = .48, respectively) after RDN with low heterogeneity (I2 = 0; I2 = 19%, respectively). The details were presented in Figure 4A and Figure 4B. No significant publication bias was found (Egger test = 0.9702 and Begg test = 1.7485 for sodium; Egger test = 0.3387 and Begg test = 0.7555 for potassium). FIGURE 4Open in figure viewerPowerPoint (A) Forest plot and funnel plot of overall serum sodium level before and after RDN. (B) Forest plot and funnel plot of overall serum potassium level before and after RDN C. Forest plot and funnel plot of overall 24 h urinary sodium level before and after RDN D. Forest plot and funnel plot of overall 24 h urinary potassium level before and after RDN. RDN, catheter-based renal denervation Five studies reported data on changes in 24 h urinary sodium after RDN (n = 227). As shown in Figure 4C, no significant change was found (3.95 mmol/24 h, 95% CI -29.36 to 37.26, P = .82) with high heterogeneity (I2 = 78%). However, potential publication bias was detected (Egger test = <0.001, Begg test = 1.5376). Further trim-and-fill analysis was conducted to adjust potential publication bias, resulting in estimated MD = -9.63 (95% CI -33.22 to 13.96, Figure S1). As for 24 h urinary potassium, data was available in two studies (n = 56), and no significant difference was found (10.22 mmol/24 h, 95% CI -12.11 to 32.54, P = .37) with relatively high heterogeneity (I2 = 70%, Figure 4D). 4 DISCUSSION To the best of our knowledge, this study is the first meta-analysis discussing the effects of catheter-based RDN on renin, aldosterone, catecholamines, sodium and potassium. Our study indicated that plasma renin significantly decreased after catheter-based RDN, while no significant change was found regarding plasma aldosterone, catecholamines, serum and urinary sodium and potassium. Afferent and efferent nerves in the kidney are an important part of the whole nervous system, which are closely associated with the pathophysiology of hypertension.34 Afferent sensory nerves are mostly located in the renal pelvic area,35 functioning by projecting signals to the central nervous system, thus regulating systemic sympathetic activity, increasing total vascular resistance and raising BP. In contrast, efferent sympathetic nerves distribute widely in all parts of renal vasculature and nephrons, innervating three general targets in the kidney, including juxtaglomerular apparatus, vascular smooth muscle, and the entire tubular system.36 Therefore, the activation of efferent nerves can theoretically affect BP levels in multiple ways: 1. Increasing the secretion of circulating renin from the juxtaglomerular apparatus and activating the renin-angiotensin-aldosterone system (RAAS); 2. Constricting vessels, increasing regional vascular resistance, and decreasing blood flow in the kidney; 3. Promoting the absorption of sodium and water, and regulating blood volume. Interruption of the above processes has been considered to partially account for the antihypertensive effect of catheter-based RDN, which may be potentially reflected in the changes in circulating renin, aldosterone, catecholamines, and serum and urinary electrolytes after the surgery. Various studies have reported relative data, while perspectives of whether such changes existed varied from each other. RDN and RAAS The effect of RDN on RAAS has been proved in animal models as presented by previous literature.37, 38 Nevertheless, conclusions drawn from clinical trials remained inconsistent. From the results of our meta-analysis we can see, the pooled data on PRA showed a significant decrease after RDN procedure. The robustness of the summarizing results was confirmed by low heterogeneity. Additionally, according to the results of meta-regression analyses, higher baseline PRA seemed to be associated with higher ambulatory SBP reduction after RDN. Guido and associates39 revealed that plasma aldosterone and PRA tended to decease after 3 months, and a statistically significant reduction at the 6 months after RDN. While the BP reduction observed in their study preceded by weeks the changes in RAAS hormones, so the conclusion was drawn that the activation of RAAS was not involved in BP control among patients after RDN. On the contrary, SYPRAL HTN-OFF MED trial23 indicated that plasma aldosterone and PRA decreased significantly after RDN, and higher baseline PRA was associated with greater reduction in both office and 24 h BP after RDN procedure. That study was designed as RCT, and patients enrolled were all off antihypertensive medication, which could exclude the confounding impact that medications brought and increased the reliability of results. According to our study, plasma aldosterone did not change significantly after RDN. While the results presented great heterogeneity, with an I2 up to 86%. As we all know, there were many factors affecting the measurement of RAAS hormones. Antihypertensive drugs were one of the most common influencing factors encountered in clinical settings, which could reduce the accuracy of results.40 As reported in SYPRAL HTN-OFF MED trial,23 plasma aldosterone was observed to decrease after RDN, when patients were without medications. We presumed that the uneven quality of studies included might contribute to the negative results in our article, and further studies with rigorous designs are warranted to confirm the effect of RDN on RAAS and the role RAAS plays in BP control after RDN procedure. RDN and catecholamines As a marker of the total sympathetic tone, pooled plasma norepinephrine presented no significant change after catheter-based RDN in our study. Nor did other catecholamines hormones as reported by previous publications.20, 21 The results from SYMPLICITY-1 trial showed that renal norepinephrine spillover reduced after RDN.41 Several possibilities might account for the negative results in plasma samples: 1. The specific inactivation and metabolism mechanisms, and the short half-life of plasma catecholamines42; 2. Inadequate ablation of sympathetic nerves during RDN; 3. Peripheral catecholamines depend not enough on the innervation of afferent and efferent nerves; 4. Lack of high-quality evidence to detect such alterations in catecholamines. After all, contradicted result was seen in another study,25 that plasma norepinephrine did decrease after RDN. RDN and electrolytes Neither change in serum nor urinary electrolytes after RDN was found from our pooled data. Several experimental studies indicated that sodium excretion increased in the short-term after RDN.43 In humans, Ott C and associates24 also reported a significant decrease in potassium excretion 1 day after RDN, while no change was observed at the 6-month follow-up. It was not surprising to find such alterations were eliminated in the long term, since human bodies possess complicated mechanisms for maintaining electrolytes homeostasis.44 Limitations This study had several limitations. First, heterogeneity associated with pooled plasma aldosterone, plasma norepinephrine, and urinary electrolytes might have reduced evidence quality. In addition, studies lacking available data, or presenting data in inappropriate forms were not included in this study. Too few studies reported on urinary catecholamines data to allow for meta-analysis. More studies with high quality standards and uniform outcome measures were urgently needed to validate the effect of RDN on BP control. 5 CONCLUSION Catheter-based RDN appeared to have effects on RAAS to some extent. Plasma renin activity significantly decreased after catheter-based RDN, while no significant change was observed regarding plasma aldosterone, plasma norepinephrine, and serum and urinary electrolytes. Higher baseline PRA seemed to be related to greater BP reduction after RDN, which indicated that patients with high PRA might be more well-responsive to the treatment. This study might help to confirm the mechanism of RDN regulating BP, and to target the potential patients. AUTHOR CONTRIBUTIONS Study concept and design-Xiangyu Yang, Zhipeng Zhang, Xiaoping Chen; Literature search and screen-Xiangyu Yang, Lede Lin; Data extraction-Xiangyu Yang, Lede Lin; Analysis and interpretation of data-Xiangyu Yang, Lede Lin; Drafting of the manuscript-Xiangyu Yang, Lede Lin; Critical revision of the manuscript for important intellectual content-Zhipeng Zhang, Xiaoping Chen. ACKNOWLEDGEMENTS The authors acknowledge and thank all participated students and teachers in Dr Xiaoping Chen's team. This study was funded by National Natural Science Foundation of China (No. 81900404 and No. 81970355). CONFLICT OF INTEREST The authors declare that they have no conflict of interest. Supporting Information Filename Description jch14590-sup-0001-FigureS1.tif3 MB Supporting information jch14590-sup-0002-TableS1.docx13.6 KB Supporting information jch14590-sup-0003-SupplementaryFile.docx15.7 KB Supporting information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455): 217- 223. 2Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama. 2013; 310(9): 959- 968. 3Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015; 28(3): 355- 361. 4Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390(10108): 2160- 2170. 5Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018; 391(10137): 2335- 2345. 6Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018; 391(10137): 2346- 2355. 7Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999; 34(4 Pt 2): 724- 728. 8Weber MA, Mahfoud F, Schmieder RE, et al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv. 2019; 12(12): 1095- 1105. 9Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. 10Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018; 27(6): 1785- 1805. 11Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14: 135. 12Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020; 38(10): 1919- 1928. 13Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9): 712- 716. 14Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011; 19(7-8): 319- 323. 15Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012; 5(7): 758- 765. 16Wang L, Lu CZ, Zhang X, et al. The effect of catheter based renal synthetic denervation on renin-angiotensin-aldosterone system in patients with resistant hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2013; 41(1): 3- 7. 17Hamza M, Khamis H. Renal sympathetic denervation for treatment of resistant hypertension: egyptian experience. J Interv Cardiol. 2014; 27(4): 423- 427. 18Poss J, Ewen S, Schmieder RE, et al. Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol. 2015; 104(8): 672- 678. 19Ewen S, Cremers B, Meyer MR, et al. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens. 2015; 33(12): 2519- 2525. 20Dobrowolski LC, Eeftinck Schattenkerk DW, Paul Krediet CT, et al. Renal sympathetic nerve activity after catheter-based renal denervation. Ejnmmi Res. 2018; 8. 21Feyz L, van den Berg S, Zietse R, Kardys I, Versmissen J, Daemen J. Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst. 2020; 21(3):1470320320943095. 22Kim CJ, Chang K, Kim BK, Park CG, Jang Y. An open-label, single-arm, multicenter feasibility study evaluating the safety of catheter-based renal denervation with DENEX™ in patients with uncontrolled hypertension on standard medical therapy. Korean Circ J. 2021; 51(1): 43- 55. 23Mahfoud F, Townsend RR, Kandzari DE, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021; 77(23): 2909- 2919. 24Ott C, Kopp C, Dahlmann A, et al. Impact of renal denervation on tissue Na(+) content in treatment-resistant hypertension. Clin Res Cardiol. 2018; 107(1): 42- 48. 25Ezzahti M, Moelker A, Friesema EC, van der Linde NA, Krestin GP, van den Meiracker AH. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension. J Hypertens. 2014; 32(1): 135- 141. 26Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephro. 2012; 23(7): 1250- 1257. 27Hering D, Lambert EA, Marusic P, et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens. 2013; 31(9): 1893- 1900. 28Hering D, Marusic P, Walton AS, et al. Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. Int J Cardiol. 2016; 202: 388- 393. 29Rosa J, Widimsky P, Waldauf P, et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. J Hypertens. 2017; 35(5): 1093- 1099. 30Kampmann U, Mathiassen ON, Christensen KL, et al. Effects of renal denervation on insulin sensitivity and inflammatory markers in nondiabetic patients with treatment-resistant hypertension. J Diabetes Res. 2017; 2017:6915310. 31Tsioufis C, Papademetriou V, Tsiachris D, et al. Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden. J Hum Hypertens. 2014; 28(10): 587- 593. 32Undrum Bergland O, Larstorp ACK, Lund Søraas C, et al. Changes in sympathetic nervous system activity after renal denervation: results from the randomised Oslo RDN study. Blood Press. 2020; 30(3): 154- 164. 33Vuignier Y, Grouzmann E, Muller O, et al. Blood pressure and renal responses to orthostatic stress before and after radiofrequency renal denervation in patients with resistant hypertension. Front Cardiovasc Med. 2018; 5: 42. 34Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015; 21: 20- 24. 35Marfurt CF, Echtenkamp SF. Sensory innervation of the rat kidney and ureter as revealed by the anterograde transport of wheat germ agglutinin-horseradish peroxidase (WGA-HRP) from dorsal root ganglia. J Comp Neurol. 1991; 311(3): 389- 404. 36Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol. 2017; 7(2): 263- 320. 37Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012; 59(2): 331- 338. 38Wang M, Han W, Zhang M, et al. Long-term renal sympathetic denervation ameliorates renal fibrosis and delays the onset of hypertension in spontaneously hypertensive rats. Am J Transl Res. 2018; 10(12): 4042- 4053. 39Grassi G, Seravalle G, Brambilla G, et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension. 2015; 65(6): 1209- 1216. 40Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012; 44(3): 170- 176. 41Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373(9671): 1275- 1281. 42Grouzmann E, Lamine F. Determination of catecholamines in plasma and urine. Best Pract Res Clin Endocrinol Metab. 2013; 27(5): 713- 723. 43DiBona GF. Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005; 289(3): R633- 641. 44Yamazaki O, Ishizawa K, Hirohama D, Fujita T, Shibata S. Electrolyte transport in the renal collecting duct and its regulation by the renin-angiotensin-aldosterone system. Clin Sci (Lond). 2019; 133(1): 75- 82. Volume24, Issue12December 2022Pages 1537-1546 FiguresReferencesRelatedInformation